Cyclic 3′,5′-guanosine monophosphate-dependent protein kinase inhibits colon cancer cell adaptation to hypoxia

Cancer

Volumn 117, Issue 23, 2011, Pages 5282-5293

  Kwon, In Kiu ^a   Wang, Rui ^a   Prakash, Nikhil ^a   Bozard, Renee ^a   Baudino, Troy A ^b   Liu, Kebin ^a   Thangaraju, Muthusamy ^a   Dong, Zheng ^a   Browning, Darren D ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b TEXAS A M COLLEGE OF MEDICINE   (United States)

Author keywords

angiogenesis; colon; cyclic 3 ; 5 guanosine monophosphate; hypoxia; kinase

Indexed keywords

ADENOSINE TRIPHOSPHATE; CYCLIC GMP DEPENDENT PROTEIN KINASE; HEXOKINASE; HEXOKINASE 2; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; UNCLASSIFIED DRUG; VASCULOTROPIN; HYPOXIA INDUCIBLE FACTOR 1;

ADAPTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL HYPOXIA; CELL NUCLEUS; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INDUCTION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ANIMAL; COLON TUMOR; METABOLISM; NECROSIS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; VASCULARIZATION;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; CELL HYPOXIA; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYCLIC GMP-DEPENDENT PROTEIN KINASES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MICE; NECROSIS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 81755184360     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26192     Document Type: Article

References (42)

1. Browning DD,. Protein kinase G as a therapeutic target for the treatment of metastatic colorectal cancer. Expert Opin Ther Targets. 2008; 12: 367-376. (Pubitemid 351419429)
2. Browning D, Kwon IK, Wang R,. The cGMP-dependent protein kinases as potential targets for colon cancer prevention and treatment. Future Med Chem. 2010; 2: 65-80.
3. Carrithers SL,. Diarrhea or colorectal cancer: can bacterial toxins serve as a treatment for colon cancer? Proc Natl Acad Sci U S A. 2003; 100: 3018-3020. (Pubitemid 36356528)
4. Pitari GM, Zingman LV, Hodgson DM, et al. Bacterial enterotoxins are associated with resistance to colon cancer. Proc Natl Acad Sci U S A. 2003; 100: 2695-2699. (Pubitemid 36297561)
5. Shailubhai K, Yu HH, Karunanandaa K, et al. Uroguanylin treatment suppresses polyp formation in the Apc(Min/+) mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP. Cancer Res. 2000; 60: 5151-5157.
6. Uzzau S, Fasano A,. Cross-talk between enteric pathogens and the intestine. Cell Microbiol. 2000; 2: 83-89. (Pubitemid 30368023)
7. Li P, Schulz S, Bombonati A, et al. Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity. Gastroenterology. 2007; 133: 599-607. (Pubitemid 47187356)
8. Lin JE, Li P, Snook AE, et al. The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling. Gastroenterology. 2010; 138: 241-254.
9. Ruth P,. Cyclic GMP-dependent protein kinases: understanding in vivo functions by gene targeting. Pharmacol Ther. 1999; 82: 355-372. (Pubitemid 29255930)
10. Lincoln TM, Dey N, Sellak H,. Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. J Appl Physiol. 2001; 91: 1421-1430. (Pubitemid 32803941)
11. Francis SH, Corbin JD,. Cyclic nucleotide-dependent protein kinases: intracellular receptors for cAMP and cGMP action. Crit Rev Clin Lab Sci. 1999; 36: 275-328. (Pubitemid 29431414)
12. Liu L, Li H, Underwood T, et al. Cyclic GMP-dependent protein kinase activation and induction by exisulind and CP461 in colon tumor cells. J Pharmacol Exp Ther. 2001; 299: 583-592. (Pubitemid 32979671)
13. Deguchi A, Thompson WJ, Weinstein IB,. Activation of protein kinase G is sufficient to induce apoptosis and inhibit cell migration in colon cancer cells. Cancer Res. 2004; 64: 3966-3973. (Pubitemid 38697311)
14. Zhu B, Vemavarapu L, Thompson WJ, Strada SJ,. Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells. J Cell Biochem. 2005; 94: 336-350. (Pubitemid 41420312)
15. Goluboff ET,. Exisulind, a selective apoptotic antineoplastic drug. Expert Opin Investig Drugs. 2001; 10: 1875-1882.
16. Haanen C,. Sulindac and its derivatives: a novel class of anticancer agents. Curr Opin Investig Drugs. 2001; 2: 677-683. (Pubitemid 32509691)
17. Soh JW, Mao Y, Kim MG, et al. Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase 1. Clin Cancer Res. 2000; 6: 4136-4141.
18. Thompson WJ, Piazza GA, Li H, et al. Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 2000; 60: 3338-3342. (Pubitemid 30482142)
19. Cen B, Deguchi A, Weinstein IB,. Activation of protein kinase G increases the expression of p21CIP1, p27KIP1, and histidine triad protein 1 through Sp1. Cancer Res. 2008; 68: 5355-5362.
20. Kwon IK, Wang R, Thangaraju M, et al. PKG inhibits TCF signaling in colon cancer cells by blocking beta-catenin expression and activating FOXO4. Oncogene. 2010; 9: 3423-3434.
21. Hou Y, Wong E, Martin J, Schoenlein PV, Dostmann WR, Browning DD,. A role for cyclic-GMP dependent protein kinase in anoikis. Cell Signal. 2006; 18: 882-888. (Pubitemid 43208941)
22. Hou Y, Gupta N, Schoenlein P, et al. An anti-tumor role for cGMP-dependent protein kinase. Cancer Lett. 2006; 240: 60-68. (Pubitemid 44037177)
23. Kwon IK, Schoenlein PV, Delk J, et al. Expression of cyclic guanosine monophosphate-dependent protein kinase in metastatic colon carcinoma cells blocks tumor angiogenesis. Cancer. 2008; 112: 1462-1470. (Pubitemid 351441158)
24. Browning DD, McShane M, Marty C, Ye RD,. Functional analysis of type 1alpha cGMP-dependent protein kinase using green fluorescent fusion proteins. J Biol Chem. 2001; 276: 13039-13048.
25. Fuseler JW, Bedenbaugh A, Yekkala K, Baudino TA,. Fractal and image analysis of the microvasculature in normal intestinal submucosa and intestinal polyps in Apc(Min/+) mice. Microsc Microanal. 2008; 16: 73-79.
26. Baudino TA, McKay C, Pendeville-Samain H, et al. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev. 2002; 16: 2530-2543.
27. Shaw RJ,. Glucose metabolism and cancer. Curr Opin Cell Biol. 2006; 18: 598-608. (Pubitemid 44692479)
28. Kim JW, Dang CV,. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res. 2006; 66: 8927-8930. (Pubitemid 44521105)
29. Gordan JD, Simon MC,. Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr Opin Genet Dev. 2007; 17: 71-77. (Pubitemid 46109295)
30. Poon E, Harris AL, Ashcroft M,. Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Rev Mol Med. 2009; 11: e26.
31. Liao D, Johnson RS,. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev. 2007; 26: 281-290. (Pubitemid 47101669)
32. Bergers G, Benjamin LE,. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003; 3: 401-410. (Pubitemid 37328844)
33. Kerbel RS,. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science. 2006; 312: 1171-1175. (Pubitemid 43801134)
34. Jain RK, Duda DG, Willett CG, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol. 2009; 6: 327-338.
35. Schmidt C,. Why do tumors become resistant to antiangiogenesis drugs? J Natl Cancer Inst. 2009; 101: 1530-1532.
36. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS,. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009; 15: 232-239.
37. Loges S, Mazzone M, Hohensinner P, Carmeliet P,. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell. 2009; 15: 167-170.
38. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009; 15: 220-231.
39. Kang X, Li J, Zou Y, et al. PIASy stimulates HIF1α SUMOylation and negatively regulates HIF1α activity in response to hypoxia. Oncogene. 2010; 29: 5568-5578.
40. Kalousi A, Mylonis I, Politou AS, Chachami G, Paraskeva E, Simos G,. Casein kinase 1 regulates human hypoxia- inducible factor HIF-1. J Cell Sci. 2010; 123 (pt 17): 2976-2986.
41. Kaidi A, Williams AC, Paraskeva C,. Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat Cell Biol. 2007; 9: 210-217. (Pubitemid 46420864)
42. Giles RH, Lolkema MP, Snijckers CM, et al. Interplay between VHL/HIF1alpha and Wnt/beta-catenin pathways during colorectal tumorigenesis. Oncogene. 2006; 25: 3065-3070. (Pubitemid 43780471)